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1. Introduction 
Radiotherapy is widely used in breast cancer treatment, particularly in patients undergoing 
breast conserving surgery, principally in order to reduce risk of local recurrence (Liljegren et 
al. 1999; Fisher et al. 2002). Although radiation therapy has been observed in a major meta-
analysis to confer a net survival benefit (Clarke et al. 2005), it is not without side-effects. It 
has been observed to confer increased risks of cardiovascular events and lung tumours 
(Clarke et al. 2005; Darby et al. 2005). The fact that radiation therapy confers both benefits 
and harms raises issues pertinent to all treatments, i.e., the importance of selecting patient 
populations for which the balance of benefits to harms is optimised, and of excluding those 
patients who will not benefit from the treatment, or at least not sufficiently to outweigh the 
risk of adverse effects. Given the current lack of confidence that the prognostic indicators for 
such selection exist, conservative therapy includes post-surgical radiotherapy as a standard 
of care. 
It has been reported that patients with invasive breast tumours less than 15 mm in size 
have mammographic tumour features that are good indicators of prognosis, and in 
particular, good long term survival has been observed in stellate lesions of this size 
without accompanying calcifications or with only non-specific calcifications (Smith et al. 
2004; Tabar et al. 2000). The large majority of these patients did not receive adjuvant 
therapy other than radiotherapy, and since long-term survival was very high, the 
potential for modern adjuvant therapies to further improve upon the survival of these 
cases is very small. However, the extent to which these patients benefited from 
radiotherapy, in terms of reduction of risk of local recurrence, is not known. In this paper, 
we review the treatment and tumour features of 425 stellate invasive breast cancers of 
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maximum diameter less than 15 mm, with a view to developing an index of risk of local 
recurrence and possibly of identifying patient populations suitable and unsuitable for 
radiotherapy. The research was approved by the Ethics Committee of Falun Central 
Hospital. 
2. Patient data obtained for analysis  
Mammograms were retrieved of all tumours of pathological size less than 15 mm, 
diagnosed in women aged 40-69 between 1977 and 1998 in Falun Central Hospital, Sweden. 
Of these, 425 were identified to have stellate appearance and either no calcifications or non-
specific calcifications on the mammogram. Patient charts were retrieved and additional 
pathological information was obtained on exact tumor size in mm, node status, tumor grade 
and histological type. Treatment details with respect to surgery, adjuvant radiotherapy, 
chemotherapy and hormonal therapy were also retrieved. In addition, we recorded age, date 
of diagnosis, mode of detection (screening or symptomatic) and follow-up details including 
dates of local recurrence, death from breast cancer and death from other causes.  
There was an average follow-up of 10.4 years to recurrence, death or last known date alive 
and disease-free, and a maximum follow-up of 27.9 years. The most recent date of follow-up 
was 20th March 2006. Local recurrence was defined as the occurrence of a histologically 
confirmed in situ or invasive carcinoma in the ipsilateral breast after treatment of the first 
breast cancer was completed.  
3. Radiotherapy treatment regimens 
For women who had breast conserving surgery for an invasive breast cancer, radiotherapy 
was regarded as standard treatment and computer dose-planned photon beam (6 and/or 15 
MV) treatment was used. Care was taken not to treat the ipsilateral lung and, in the case of 
left-sided breast cancers, the heart. The whole breast parenchyma was defined as the target 
and 2 Gray per fraction times 25 was delivered over 5 weeks. If the patient was younger 
than age 45 yrs or if extensive DCIS (>25% of tumor) was present, additional photon-boost 
was used against the tumor bed. The boost-target was treated with 2 Gy per fraction to a 
total of 10 - 16 Gray.  If one or more lymph nodes were engaged with cancer, separate fields 
were directed to the ipsilateral axilla and supraclavicular fossa, 2 Gray per fraction x 25 was 
used. Treatment of the intramammary lymph nodes was considered if 4 or more of the 
axillary nodes were metastasized. 
Computer dose-planned radiotherapy was used also for some patients treated with a 
mastectomy. The thoracic wall was treated with opposed tangential photon fields if the 
tumor was > 30 mm or multifocal or N1. Regional lymph nodes were treated according the 
rules described above. Boost treatment was given only in the rare instances when surgical 
radicality could not be achieved. 
4. Multifactor score of risk of recurrence 
Data were analysed by stepwise Cox proportional hazards regression to build up a 
multifactor score of risk of recurrence. Analyses were adjusted for age and epoch of 
diagnosis, as radiotherapy practices depended on these factors. After exclusion of those 
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factors that were not statistically significant when adjusted for other variables, we used the 
final Cox regression model to estimate the absolute reductions in 15-year risk of recurrence 
(only 22% of subjects had follow-up in excess of 15 years). 
5. Recurrence rates in patients with small stellate breast cancers 
Survival in this group was generally excellent. Figure 1 shows survival by size group (1-9 
mm and 10-14 mm) and radiotherapy. In all four groups, long-term survival was 90% or 
greater. There was no significant effect of radiotherapy on survival. 
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Fig. 1. Breast cancer specific survival of 425 1-14 mm stellate invasive breast cancers by size 
group and radiotherapy. 
Table 1 shows the study subjects and recurrence rates by tumour, host, diagnostic and 
treatment features. There were 70 local recurrences in 425 patients. Overall, the average rate 
of recurrence was 1.6% per annum. Notably high recurrence rates were observed in grade 3 
tumours and lobular carcinoma cases. Because 51% of the cases were diagnosed before 1990, 
the proportions of subjects treated with breast conserving surgery and with hormone 
therapy were considerably smaller than would be the case in tumours diagnosed at the 
present time.  
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Factor Category Cases (%) Recurrences Crude annual % 
recurrence rate 
Epoch of 
diagnosis 
1977-84 117 (28) 20 1.4 
1985-89 99 (23) 18 1.5 
1990-94 99 (23) 19 2.0 
1995-98 110 (26) 3 1.7 
Age group <55 142 (33) 26 1.5 
55+ 283 (67) 44 1.6 
Tumour size 
(mm) 
1-9 156 (37) 25 1.6 
10-14 269 (63) 45 1.6 
Node status Negative 341 (80) 55 1.5 
Positive 45 (11) 10 2.0 
Not examined 39 (9) 5 1.7 
Grade 1 204 (50) 24 1.1 
2 173 (42) 31 1.8 
3 34 (8) 10 2.9 
Unknown 14 5 4.1 
Surgery Mastectomy 136 (32) 21 1.3 
BCS* 289 (68) 49 1.7 
Radiotherapy No 168 (40) 31 1.7 
Yes 254 (60) 38 1.5 
Unknown 3 1 3.3 
Chemotherapy No 411 (97) 67 1.6 
Yes 12 (3) 3 2.9 
Unknown 2 0 0.0 
Hormone therapy No 391 (92) 64 1.5 
Yes 32 (8) 6 2.4 
Unknown 2 0 0.0 
Histological type Ductal 286 (67) 47 1.6 
Lobular 52 (12) 14 2.8 
Tubular 80 (19) 7 0.8 
Other 7 (2) 2 2.9 
Detection mode Symptomatic 102 (24) 22 2.0 
Screening 323 (76) 48 1.4 
* BCS=breast conserving surgery 
Table 1. Host, tumour and treatment characteristics, with the corresponding rates of local 
recurrence. 
Table 2 shows the final model from the stepwise Cox regression for prediction of recurrence. 
Age and epoch of diagnosis were included regardless of significance. A highly significant 
increase in risk of recurrence was noted with grade (HR=1.93, 95% CI 1.31-2.85, p=0.001, trend 
test). Although the main effect of radiotherapy was not significant, it had a significant 
interaction with age (p=0.03), associated with lower rates of recurrence in patients aged 55 and 
over (HR=0.26, 95% CI 0.07-0.88), but not in patients aged less than 55. It also had a borderline 
significant interaction with histological type (p=0.07) with a high rate of recurrence in lobular 
carcinoma cases treated with radiotherapy (HR=3.58, 95%CI 0.90-14.13). The effects of BCS 
(p=0.01) and histological type (p=0.04) were significant before adjustment for these 
interactions, so these factors were retained in the model. No other variables had significant 
effects on risk of recurrence after adjustment for the factors in Table 2. 
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Factor Category Cox regression RR* 95% CI 
Age group <55 1.00 - 
55+ 2.53 0.93-6.87 
Epoch of 
diagnosis 
1977-84 1.00 - 
1985-89 1.19 0.55-2.53 
1990-94 2.15 0.95-4.82 
1995-98 1.42 0.55-3.04 
Surgery Mastectomy 1.00 - 
BCS 1.81 0.93-3.51 
Histology Ductal, other 1.00 - 
Lobular 0.92 0.31-2.76 
Grade Trend 1.93 1.31-2.85 
Radiotherapy No 1.00 - 
Yes 1.21 0.40-3.62 
Interaction Lobular AND radiotherapy 3.58 0.90-14.13 
Interaction Age 55+ AND radiotherapy 0.26 0.07-0.88 
* RR=rate ratio 
Table 2. Relative hazards and 95% confidence intervals from the final Cox regression model 
after stepwise regression. 
Table 3 shows the results from the final Cox regression model, in terms of estimated annual 
rates of recurrence in the absence of radiotherapy and absolute reductions in cumulative 15-
year recurrence associated with radiotherapy. Overall, absolute effects were small. For 
example, for grade 1, non-lobular tumours, in women aged 55 or older, treated with 
mastectomy, the absolute reduction in risk of local recurrence associated with radiotherapy 
was 1.87%. Substantial reductions in recurrence rates were observed only for cases aged 55 
or more at diagnosis, of grade 2 or 3 and of non-lobular histological type. For some 
combinations of factors, notably lobular carcinoma cases younger than age 55, the 
reductions were negative, i.e. showing increases in recurrence in those treated with 
radiotherapy. For lobular carcinoma cases age 55 or over, and for non-lobular cases younger 
than age 55, no substantial benefit of radiotherapy was observed. 
6. Expert commentary 
This study pertains to a very special subgroup of good prognosis tumours, i.e. stellate 
lesions less than 15 mm in size without calcifications. Within this group, our results suggest 
that radiotherapy was substantially beneficial only in terms of preventing local recurrence in 
women aged 55 and older diagnosed with non-lobular carcinoma grade 2 or 3, a subgroup 
constituting 31% of the subjects (131 out of 425). Of the remaining 294 cases, 183 (63%) 
received radiotherapy, and based on these results not only did not substantially benefit from 
it, but may indeed have had their risk of recurrence increased. It might be argued that in 
modern treatment practice, very few of the mastectomy cases would receive radiotherapy. 
Where margins are close, the NCCN recommends that radiotherapy should be considered 
(NCCN 2009).  However, also in modern therapeutic practice, a large proportion of these 
cases, being smaller than 15 mm, would receive wide local excision. 
Radiotherapy is primarily aimed at reducing the risk of local recurrence (Liljegren 2002). It 
has been suggested that radiotherapy might be dispensed with for low-risk patients (e.g.  
www.intechopen.com
 
Imaging of the Breast – Technical Aspects and Clinical Implication 
 
222 
Surgery Age Lobular 
histology 
Grade Estimated % 
annual 
recurrence 
rate without 
radiotherapy 
Absolute reduction 
in 15-year 
probability of 
recurrence with 
radiotherapy 
Mastectomy <55 No 1 0.5 -0.0007 
 2 0.9 -0.0026 
 3 1.7 -0.0115 
Yes 1 0.4 -0.0114 
 2 0.9 -0.0360 
 3 1.7 -0.0748 
55+ No 1 1.2 0.0187 
 2 2.3 0.0570 
 3 4.5 0.1470 
Yes 1 1.1 -0.0030 
 2 2.2 -0.0084 
 3 4.2 -0.0235 
Breast 
conserving 
surgery 
<55 No 1 0.9 -0.0036 
 2 1.7 -0.0088 
 3 3.2 -0.0228 
Yes 1 0.8 -0.0319 
 2 1.6 -0.0882 
 3 3.0 -0.1800 
55+ No 1 2.2 0.0504 
 2 4.2 0.1363 
 3 8.3 0.2769 
Yes 1 2.0 -0.0078 
 2 3.9 -0.0220 
 3 7.6 -0.0340 
Table 3. Estimated recurrence rates in the absence of radiotherapy and absolute reduction in 
15-year risk of recurrence by surgery, age, histological type and grade of tumours, from the 
final Cox regression model. 
older patients with lower stage non-lobular tumours) (Liljegren 2002; Liljegren et al. 1997).  
One study has found risk of recurrence to be particularly low in those with non-dense breast 
tissue (Cil et al. 2009). The results here suggest that a significant proportion of patients with 
small stellate lesions can be considered at low risk, and that some higher risk patients, such 
as lobular carcinoma cases, may have high local recurrence rates despite radiotherapy. 
These results are observational, and need to be validated.  
Another observational study has found, contrary to our results, that radiotherapy is associated 
with substantially reduced risk of local recurrence in lobular carcinoma (Diepenmaat et al. 
2009). There was, however, a comparatively shorter follow up time (median of 7.2 years). 
Issues such as this may be resolved by delineating the tumour populations in radiotherapy 
trials which have already been conducted, or by carrying out new prospective trials.  
The point has already been made that small stellate lesions are a good candidate for less 
aggressive therapy (Smith et al. 2004; Alexander, Yankaskas, and Biesemier 2006). The 
potential to save almost 70% of patients in this group from the hazards of radiation therapy 
is a goal worth pursuing. 
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7. Five year view 
The results of this observational study suggest that contrary to standard practice, post-
operative radiotherapy may not be the ideal treatment for all breast cancers treated with 
breast conserving surgery, particularly those with good prognosis. This is not to deny the 
results of the randomised trials and meta-analyses. There is clear evidence from these that 
radiotherapy reduces local recurrence and improves survival. However, this does not 
necessarily imply that it is needed in all cases. There is potential for utilising patient and 
tumour information to assign treatment based on that which is appropriate for the 
subgroup. This tailored therapeutic approach uses simply obtained specifics, e.g patient age, 
radiological appearance and tumour histology/grade. It would enable a more accurate risk-
benefit analysis to be calculated before prescription of therapies with adverse side-effects 
such as radiotherapy. It is therefore attractive in comparison with universal provision of 
radiotherapy to all patients. Before such policies can be implemented, it is essential that we 
are certain of the risks:benefit ratio for each patient subgroup and therefore these findings 
must be validated. This approach of investigating the level of benefit to different patient 
populations may be useful for other cancer therapies with adverse side-effects, with the 
objective of identifying other areas for improvement as medical oncology progresses to an 
era of individually tailored treatments. 
8. Conclusion 
Radiotherapy is widely used to reduce the risk of local recurrence of breast cancer, 
particularly after breast conserving surgery. However, radiotherapy to the breast has 
adverse long-term side effects (risk of heart disease, lung cancer, angiosarcoma, 
deformation), and therefore it would be useful to identify subsets of patients for whom this 
treatment is unnecessary. Patients with stellate tumours of 1-14mm have a good prognosis 
and a high proportion of them might benefit from omitting radiotherapy. A Cox regression 
was applied to follow up data from 425 such patients and a comparison of local recurrence 
rates made for different patient groups/tumour stages receiving or not receiving 
radiotherapy post surgery. These observations suggest that the only group of patients 
within the 1-14 mm stellate lesions to benefit from radiotherapy are those aged 55 or more, 
with high grade (2 or 3) disease and non-lobular histology. Radiotherapy may not be 
beneficial to certain groups with higher risk of recurrence (e.g. younger women or lobular 
carcinoma) and some groups with low risk of recurrence (e.g. low grade tumours). Further 
validation using subgroup analyses of trials already performed would be useful. 
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